Metastatic Progression of Human Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (1 January 2024) | Viewed by 46979
Special Issue Editors
Interests: melanoma; progression; genomics; signaling
Special Issue Information
Dear Colleagues,
Melanoma is the most metastatic human cancer, and can progress even from a very small sub-millimeter-sized primary. Accordingly, to understand the biology behind it may not only reveal the unique molecular determinants of this biology but may also identify the common, pan-cancer characteristics of metastatic progression. This Special Issue of Cancers is dedicated to human melanoma progression. Although there were fundamental improvements in the management of the metastatic disease of melanoma patients, the disease itself is still not curable when it becomes metastatic. To further improve the treatment of melanoma, we have to better understand the biology, the genetic background behind, the unique immunology of melanoma, and most importantly, the background of therapy resistance: chemo-, targeted or immunological. We expect submissions for this endeavor from researchers, molecular pathologists, immunologists and oncologists who can contribute to a better understanding of melanoma.
Prof. Dr. Jozsef Tímar
Dr. Andrea Ladányi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- human melanoma
- metastasis models
- oncogenic signaling
- organ metastasis
- genomics
- immune microenvironment
- prognosticators
- predictors of target therapies